carmustine + cyclophosphamide + dexamethasone + doxorubicin + melphalan + prednisone + vincristine

A multi-agent chemotherapy combination consisting of carmustine, cyclophosphamide, dexamethasone, doxorubicin, melphalan, prednisone, and vincristine. These are all small-molecule antineoplastic drugs with distinct mechanisms of cytotoxicity including alkylation of DNA, microtubule inhibition, topoisomerase II inhibition, and glucocorticoid receptor-mediated effects. This regimen has been primarily developed for the treatment of multiple myeloma, especially in the context of conventional and high-dose chemotherapy protocols, often as part of historical or intensification regimens. It has been studied for both newly diagnosed and relapsed or refractory multiple myeloma and was used before the adoption of modern targeted or immunomodulatory agents[6][5][1].

Other names

VBMCP/VBAD (when alternating with dexamethasone/doxorubicin for intensified regimens)VBMCP (when used without dexamethasone/doxorubicin in some protocols)VMBCP (variant name used in literature)